Preclinical
May 15, 2023 - May 19, 2023
PEGS
TriTCE Co-Stim, Next Generation Co-Stimulatory Trispecific T cell Engagers for the Treatment of Solid Tumors
Bhoiane et al.
Preclinical
May 10, 2023
STING & TLR-Targeting Therapies Summit
Evaluation of TLR7-agonists as payloads for immune-stimulating antibody conjugates
Graham Garnett
Preclinical
April 18, 2023
AACR
TriTCE Co-Stim, Next Generation Co-Stimulatory Trispecific T cell Engagers for the Treatment of Solid Tumors
Newhook et al.
Zanidatamab
April 18, 2023
AACR
ERBB2 amplification detected in ctDNA as a surrogate for tumor tissue FISH analysis of HER2 status in a Phase 1 study with zanidatamab for the treatment of locally advanced or metastatic HER2 expressing cancers
Shpektor et al.
Zanidatamab Zovodotin
April 17, 2023
AACR
Zanidatamab zovodotin (ZW49) induces hallmarks of immunogenic cell death and is active in patient-derived xenograft models of gastric cancer
Barnscher et al.
Preclinical
April 17, 2023
AACR
PROTECT™, A Novel Trispecific Antibody Masking Platform With Integrated Immune Modulation Displays Unique Activity and Differentiated Modes of Action
Von Rossum et al.
Preclinical
April 17, 2023
AACR
ZW251, a novel Glypican 3-targeting antibody drug conjugate bearing a topoisomerase I inhibitor payload
Madera et al.
Preclinical
April 17, 2023
AACR
ZW171, a T Cell-Engaging, Bispecific Antibody for the Treatment of Mesothelin-Expressing Solid Tumors
Afacan et al.
Preclinical
April 17, 2023
AACR
TriTCE CPI, Next Generation Trispecific T Cell Engagers with Integrated Checkpoint Inhibition (CPI) for the Treatment of Solid Tumors
Poffenberger et al.
Preclinical
April 17, 2023
AACR
ZW270, A Conditionally Masked IL-12 Cytokine Fusion Protein Displaying Potent Anti-tumour Activity Absent of Systemic Toxicity
Escalante et al.
Preclinical
April 17, 2023
AACR
ZW191, a novel FRα-targeting antibody drug conjugate bearing a topoisomerase I inhibitor payload
Lawn et al.
Preclinical
April 17, 2023
AACR
Revisiting the dogma of antibody drug conjugates (ADCs): Emerging data challenge the benefit of linker
stability and the primacy of payload delivery
Colombo et al.
